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ABSTRACT By using appropriate amounts of four bacte-
riophage 429 DNA replication proteins-terminal protein,
DNA polymerase, protein p6 (double-stranded DNA-binding
protein), and protein p5 (single-stranded DNA-binding pro-
tein)-it has been possible to amplify limited amounts of the
19,285-bp-long 429 DNA molecule by three orders of magni-
tude after 1 hr of incubation at 300C. Moreover, the quality of
the amplified material was demonstrated by transfection ex-
periments, in which infectivity of the synthetic (amplified) 429
DNA, measured as the ability to produce phage particles, was
identical to that of the natural 429 DNA obtained from virions.
The results presented in this paper establish some of the
requisites for the development ofisothermal DNA amplification
strategies based on the bacteriophage 429 DNA replication
machinery that are suitable for the amplification of very large
(>70 kb) segments of DNA.
The genome ofBacillus subtilis phage 429 consists of a linear
double-stranded DNA (19,285 bp), with a 6-bp-long inverted
terminal repeat and a terminal protein (TP) covalently linked
at both 5' ends (reviewed in ref. 1). Since the first proposal
by Rekosh et al. (2), by which a free molecule of TP would
act as a primer to initiate synthesis at both ends of the linear
DNA molecule, the availability of in vitro replication systems
for both adenovirus and bacteriophage 429 allowed the
confirmation of this hypothesis and the characterization of
the functional role of other replication proteins involved in
this process (reviewed in ref. 1).
As depicted in Fig. 1, initiation of 429 DNA replication
is triggered by the viral protein p6 (double-stranded DNA-
binding protein; DBP), which forms a nucleoprotein com-
plex at both 429 DNA ends, producing a conformational
change in the DNA that probably leads to local opening of
the DNA duplex (5). The primer TP forms a 1:1 complex
with 429 DNA polymerase that recognizes both ends of the
linear 429 DNA molecule (replication origins). Then, in the
presence of dATP and Mg2+, 429 DNA polymerase cata-
lyzes the formation of a covalent bond between dAMP and
the OH group of Ser-232 of the TP acting as primer (6, 7).
In this reaction, dATP is selected by base complementarity
with the second 3'-nucleotide of the template strand (8).
After this initiation step, dissociation of the TP-DNA
polymerase heterodimer is likely to occur (transition) to
replace the TP-DNA polymerase interactions required for
initiation by the DNA polymerase-DNA interactions re-
quired for the elongation of the newly created DNA primer.
Concomitantly, an asymmetric translocation (sliding back)
of only TP-dAMP, but not of the template, followed by
addition of a new dAMP residue, allows the recovery of the
information corresponding to the first template nucleotide
(8). During elongation, 429 DNA polymerase catalyzes
highly processive polymerization coupled to strand dis-
placement (9), and, therefore, complete replication of both
strands proceeds continuously from each terminal priming
event. As the two replication forks move, DNA synthesis
is initially coupled to strand displacement of long stretches
of single-stranded 429 DNA, producing type I replicative
intermediates (see Fig. 1). When the two replication forks,
moving in opposite directions, merge, a new type of repli-
cative intermediate (type II) is formed. Electron micros-
copy analysis of 429 replicative intermediates in vitro
showed that the viral protein p5 binds to the single-stranded
portion of both type I and II molecules, thus acting as a
single-stranded DNA-binding protein (SSB) during )29
DNA replication (4). Once polymerization of both strands
has been completed, the two DNA polymerase molecules
dissociate from the DNA to reassume initiation and repli-
cation of a new 429 DNA molecule.
The symmetrical mode of429DNA replication is similar in
several aspects (primed initiation at the ends of a linearDNA
molecule and continuous synthesis of both strands) to the
most widely used DNA amplification technique: PCR. How-
ever, the natural 429 DNA amplification system has signif-
icant differences derived from the nature of the primers (TP),
from the fact that both DNA ends are true replication origins
and, therefore, no thermal denaturation is required to posi-
tion primers; and from the specific strand displacement
coupled to DNA synthesis catalyzed by 429 DNA polymer-
ase, which allows this enzyme to replicate extremely long
double-stranded DNA molecules in isothermal conditions.
In this paper, as the initial step in the development of
amplification vectors based on the 429 DNA replication
machinery, we have characterized the minimal protein fac-
tors required in vitro for the efficient TP-primed amplification
of limited amounts of 429 DNA.
MATERIALS AND METHODS
Nucleotides, Proteins, and DNA Templates. Unlabeled
dNTPs and [a-32P]dNTPs (410 Ci/mmol; 1 Ci = 37 GBq) were
obtained from Amersham. 429 DNA polymerase (Mr =
66,520) and TP (Mr = 30,918) were overproduced in Esche-
richia coli cells and purified essentially as described (10, 11).
Protein p6 (Mr = 11,873) and protein p5 (Mr = 13,212),
obtained from 429-infected B. subtilis cells, were purified as
described (12, 13). TP-linked DNA from 429 susl4 (1242)
virions, isolated as described (14), was used as input template
for in vitro amplification experiments and as a control DNA
in transfection experiments.
Phage and Bacterial Strains. Bacteriophage 429 susl4
(1242) has a nonsense (sus) mutation in gene 14 (15), which
produces a delayed lysis phenotype when plated in the
nonpermissive strain B. subtilis 11ONA Try- spoA (16). B.
subtilis BG295 (Sup 3) (17) was used for transfection exper-
iments. B. subtilis MO-101-P spoA Thr- (Met-)+ Su+44 (18)
Abbreviations: TP, terminal protein; pfu, plaque-forming unit(s);
SSB, single-stranded DNA-binding protein (p5); DBP, double-
stranded DNA-binding protein (p6).
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was used as permissive host (suppressor strain) for titration
of 429 susl4 (1242).
*29 DNA Amplcn Assay. To optimize the initiation
step of 029 DNA replication, an equimolar (1:1) complex
between highly purified 429 DNA polymerase and TP was
obtained by incubation ofboth proteins in the presence of 20
mM ammonium sulfate, as described (19). The incubation
mixture contained, in 10 Il, 50mM Tris*HCl (pH 7.5), 10mM
MgCl2, 20 mM (NH4)2SO4, 1 mM dithiothreitol, 4% glycerol,
bovine serum albumin (0.1 mg/ml), 80 ALM each dCTP,
dGTP, dTTP, and [a-32P]dATP (2 AQCi), 15 ng of preformed
TP-DNA polymerase complex, and 20 ng of free TP. As
indicated, different amounts of )29 DNA (containing paren-
tal TP), obtained from phage #29 mutant susl4 (1242), were
used as input DNA template. When indicated, different
amounts of purified proteins p6 (DBP) and p5 (SSB) were
either individually or simultaneously added. After incubation
for 1 hr at 30TC, the reaction was stopped by addition of 10
mM EDTA, and the unreacted [a-32P]dATP was removed by
filtration through a Sephadex G-50 spin column in the pres-
ence of 0.1% SDS. Quantitation of the DNA synthesized in
vitro, measured as the total amount (in nanograms) of dNTP
incorporated, was carried out from the amount of radioac-
tivity (Cerenkov radiation) corresponding to the excluded
volume. When indicated, the size of the amplified DNA was
analyzed by alkaline agarose gel electrophoresis (20) fol-
lowed by autoradiography and ethidium bromide staining.
FIG. 1. Different stages and vi-
ral gene products involved in 029
DNA replication. For simplicity,
only one 4)29DNA end (replication
origin) is represented. 029 TP is
indicated in black (when acting as
primer) or shadowed (parental).
429 DNA polymerase is depicted
by a triangle. The two main types of
replicative intermediates (I and II)
produced during the elongation
stage and observed both during in
vivo (3) and in vitro (4) 4)29 DNA
replication are represented in
boxes.
Infectivi Assay for the in Vitro-Ampf ed 4¢9 DNA. In this
case, the in vitro amplification conditions were as described
above except that the input 429 DNA (0.5 ng) was incubated
with TP-DNA polymerase complex (15 ng), free TP (20 ng),
DBP (10 pg), and SSB (8 jig), in the presence of the four
unlabeled dNTPs each at 80 AM. After 2 hr at 30"C, the
reaction was stopped with 10 mM EDTA, and the DNA was
precipitated with ethanol and resuspended in 10mM Tris-HCl
(pH 7.5)/0.1 mM EDTA. As an in vivo control of infectivity,
500 ng of the 429 DNA used as input for amplification was
incubated under exactly the same conditions but in the
absence of dNTPs. After 2 hr at 300C, the control 429 DNA
was processed as described for the in vitro-amplified 4)29
DNA. Aliquots of the amplified 429 DNA were quantitated
by alkaline agarose gel electrophoresis (20) and ethidium
bromide staining. Different amounts of 429 DNA (control or
amplified) were used to transfect B. subtilis BG295 (suppres-
sor strain)-competent cells, prepared as described (21). After
transfection, infectivity, expressed as plaque-forming units
(pfu), was determined by plating on B. subtilis Su+44 sup-
pressor strain.
RESULTS
Requirements for in Vitro Amplfation of 029 DNA. It was
reported that the complete replication of both 029 DNA
strands in vitro required only two proteins: the 429 TP, which
acts as initiation primer, and the viral DNA polymerase (22).
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FIG. 2. In vitro amplification of 429 DNA. (A) DNA synthesized
in vitro with different combinations of 429 DNA replication proteins,
as a function of the amount of input 429 DNA. The 429 DNA
amplification assay was carried out as described in Materials and
Methods, in the presence of 15 ng ofpreformed TP-DNA polymerase
complex, 20 ng of free TP, and different amounts of 429 DNA
(containing parental TP) as input DNA template. When indicated, 10
pg of purified protein p6 (DBP) and 8 pg of purified protein p5 (SSB)
were added either individually (o and A) or simultaneously (e) to the
minimal system (o) previously described. After incubation for 1 hr at
30'C, the reaction was stopped and quantitated as the total amount
(in nanograms) of dNTP incorporated. (B) DNA amplification fac-
tors, corresponding to the different conditions shown in A, were
calculated as the ratio between the amount of DNA synthesized in
vitro and the amount of input 429 DNA. o, DNA polymerase + TP;
a, DNA polymerase + TP + p6; A, DNA polymerase + TP + p5; *,
DNA polymerase + TP + p6 + p5.
However, this minimal system was defined using a consid-
erable amount of 429 DNA template (0.5 Mg; 1.6 nM), and,
therefore, we reconsidered the characterization of the pro-
teins required for an efficient DNA amplification in vitro (i.e.,
starting from limited amounts of 429 DNA).
Fig. 2A shows that the amount ofDNA synthesized when
using a minimal system formed by TP and DNA polymerase
is strongly dependent on the amount of input 429 DNA.
Thus, in vitro synthesis occurred at input doses of 500 ng (4
nM) and 50 ng (0.4 nM), but it was almost undetectable at
A DNApoI+TP+p5(SSB)
input doses corresponding to 0.5 ng (4 pM) and 5 ng (0.04
nM); no reaction was observed even after overnight incuba-
tion. Therefore, initiation is probably the rate-limiting step: it
is very inefficient at low ratios between DNA replication
origins and the minimal initiation proteins (TP-DNA poly-
merase complex). As expected from previous data (23),
addition ofDBP to the in vitro minimal system produced only
a 1.5- to 2-fold increase in the amount ofDNA synthesized at
any of the input )29 DNA doses tested. Also in agreement
with previous reports (24), addition of SSB to the minimal
system produced a stimulation of about 4- to 5-fold in the
amount of synthesized DNA when starting with either 500 ng
or 50 ng of input )29 DNA; however, at the lower doses of
input DNA tested, the effect of adding SSB was negligible.
On the other hand, the simultaneous addition of viral DBP
and SSB to the minimal system resulted in a high yield of in
vitro-synthesized DNA, even when starting with either 5 ng
or 0.5 ng of input DNA template. Analysis of the titration
curves shown in Fig. 3 indicates that both DBP and SSB are
required in high amounts to obtain an efficient amplification.
Thus, in the presence of the four viral proteins, it was
possible to amplify by three orders of magnitude the amount
of input 429 DNA (see Fig. 2B). Under these conditions, an
exponential increase of in vitro-synthesized DNA could be
obtained as a function of the time of incubation (data not
shown), indicating not only a high efficiency in terms of
number of initiation events but also the occurrence of full
elongation of both DNA strands.
Size Analysis of the in Vitro-Ampliflied 029 DNA. Fig. 4
(lanes 1-4) shows the size analysis of the amplified 4)29DNA
obtained in vitro in an experiment similar to that shown in
Fig. 2, using each of the four combinations of viral proteins
and starting with 0.5 ng of input 429 DNA. Interestingly, the
amplified DNA, obtained only in the presence of the four
viral proteins (Fig. 4, lane 4), corresponded to full-length 429
DNA. Moreover, electron microscopy analysis of the DNA
amplified under these conditions indicated the accumulation
of mature 429 DNA molecules (data not shown). The am-
plification factor obtained (1460-fold) implies a maximal time
of about 6 min per duplication cycle; the amount of 429 DNA
synthesized under these conditions (730 ng/58 fmol) is close
to the limit imposed by the amount of dNTPs provided.
A delicate equilibrium (stoichiometry) of initiation and
elongation factors required for the efficient in vitro amplifi-
cation of 429 DNA can be clearly observed in Fig. 4, lanes
5-9. At a fixed concentration of DBP and SSB, a small
increase in the amount ofTP-DNA polymerase complex with
respect to the one allowing optimal amplification of full-
length 429 DNA leads to the generation of immature elon-
gation products, although the amount of DNA synthesized
was roughly similar. This result is interpreted as the conse-
quence of an imbalance between the number of initiations
(increased) and the ratio of elongation factors to growing
B DNApoI+TP+p6(DBP)
2 4 6
p5 (SSB), tg
8 10
FIG. 3. Requirement of proteins p6
(DBP) and p5 (SSB) for 4)29 DNA ampli-
fication. The 429 DNA amplification as-
say was carried out as described in Ma-
terials and Methods, but using 0.5 ng of
4)29 DNA (containing parental TP) as
input DNA template, 15 ng of preformed
TP-DNA polymerase complex, 20 ng of
free TP, and either 8 pg of SSB and
different amounts ofDBP (A) or 10 pg of
protein DBP and different amounts of
SSB (B). After incubation for 1 hr at 300C,
the reaction was stopped and quantitated
as the total amount (in nanograms) of
dNTP incorporated.
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FIG. 4. Size analysis of in vitro-amplified 429 DNA. Amplifica-
tion assays were carried out essentially as described in Materials and
Methods, using the indicated amounts of input 429 DNA. Different
429 DNA replication proteins [TP-DNA polymerase complex, p6
(DBP), and p5 (SSB)] were added as indicated. After 1 hr of
incubation at 300C, the reaction was stopped with 10mM EDTA, the
amount of synthesized DNA was quantitated as described, and the
size of the amplified DNA was analyzed by alkaline agarose gel
electrophoresis followed by autoradiography (A) and ethidium bro-
mide staining (B). The amplification factor corresponding to each
particular condition, calculated as described in the legend to Fig. 2,
is indicated. The arrows at the left indicate the electrophoretic
mobility of full-length 429 DNA obtained from virions.
DNA chains (reduced). Moreover, the size ofthe synthesized
DNA was linearly dependent on the amount ofSSB (data not
shown). On the other hand, in the absence of SSB, and using
a large amount (60 ng) of TP-DNA polymerase complex, it
was possible to observe a large stimulation in the amount of
short elongation products as a consequence of adding DBP
(Fig. 4, lanes 10 and 11). This result allows us to conclude that
binding ofDBP to the 4)29 DNA replication origins is the main
factor stimulating the initiation stage in these in vitro ampli-
fication conditions. Therefore, it is tempting to speculate
that, in addition to facilitating the opening of 429 DNA
replication origins, DBP increases the affinity of the TP-
DNA polymerase complex by the 429 DNA ends. On the
other hand, SSB, in addition to preventing the nonproductive
binding of replication proteins to the displaced strands (25),
appears to be critical for the progression (maturation) of the
multiple replication forks initiated at both 4)29 DNA replica-
tion origins.
All these results agree with the importance of the four viral
proteins for 429 DNA replication in vivo (26, 27) and also
emphasize the necessity of a precise stoichiometry of these
proteins to maintain the equilibrium between the initiation
and elongation stages of replication.
Infectivity of the in Vitro-Amplified 429 DNA. As a quality
control of the in vitro amplification procedure described in
this paper, the infectivity of the synthetic (in vitro) 429 DNA,
-
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FIG. 5. Infectivity of the in vitro-amplified 4)29 DNA. In vitro
amplification conditions were as described in Materials andMethods
for the infectivity assay. A control 429 DNA (in vivo) was processed
essentially in the same form but in the absence of dNTPs. The
indicated amounts ofeither in vivo (control) or in vitro 429DNA were
used to transfect B. subtilis BG295 (suppressor strain) competent
cells. After transfection, infectivity, expressed as pfu, was deter-
mined by plating on permissive B. subtilis Su+44 cells.
measured as the ability to produce phage 429 particles, was
compared with that of the natural (in vivo) 429 DNA. Thus,
similar amounts of 429 DNA, either obtained from 029 susl4
(1242) virions or by in vitro amplification of 429 susl4 (1242)
DNA, were used to transfect B. subtilis competent cells, and
the number ofinfective centers was determined by plating on
permissive (suppressor) B. subtilis cells. As shown in Fig. 5,
infectivity ofboth natural (in vivo) and synthetic (in vitro) 429
DNA was virtually identical; the transfection efficiency was
'104 pfu/pg. Moreover, the size distribution of individual
plaques was also identical, indicating the absence of in vitro
mutations affecting phage growth. These results indicate that
the in vitro 429 DNA amplification system produces mature
molecules and also suggest that DNA synthesis is being
carried out with high fidelity. This could be expected if one
takes into account previous estimations of the insertion
fidelity of 4)29 DNA polymerase (28) and its strong 3' -* 5'
exonuclease activity (29, 30). A minimal estimate of the
fidelity ofthis amplification system is the fact that no plaques
were obtained when the transfection mixture corresponding
to the in vitro-amplified 429 DNA was plated in nonpermis-
sive B. subtilis cells. This was the expected result if the
nonsense mutation present in the input 429 DNA was main-
tained in the in vitro-amplified 429 DNA molecules.
DISCUSSION
In this paper, one of the most efficient in vitro DNA repli-
cation systems described so far is presented. By using four
429 DNA replication proteins-TP (primer), DNA polymer-
ase, protein p6 (DBP), and protein p5 (SSB)-it has been
possible to amplify the 19,285-bp-long 429 DNA molecule by
three orders of magnitude after 1 hr of incubation at 300C. As
it occurs during 4)29 DNA replication in vivo, each of these
proteins was an absolute requirement. The biological activity
of the in vitro-amplified 429 DNA was demonstrated by its
ability to produce phage 429 particles when transfected into
B. subtilis cells.
It was expected that, under the different conditions used,
the amount of DNA synthesized (amplified) would largely
depend on the efficiency of initiation and the frequency of
reinitiations both on the same and/or different DNA mole-
cules. Moreover, elongation was not expected to be rate-
Biochemistry: Blanco et al.
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limiting because once a molecule is initiated, complete elon-
gation could be achieved in about 5 min (9). However, size
analysis of the synthesized DNA indicates that at a high ratio
among initiation factors (TP, DNA polymerase, and DBP)
and input DNA (replication origins), there is a blockage of
elongation that can be only prevented by addition of the SSB
protein. This blockage could be due to a "mechanical"
hindrance produced by the multiple displaced strands origi-
nated from frequent reinitiations at the same origin.
A variety of nucleic acid amplification techniques, devel-
oped as tools for nucleic acid analysis and manipulation, are
also being successfully applied for clinical diagnosis of ge-
netic and infectious diseases. Amplification techniques (re-
viewed in ref. 31) can be grouped into (i) those requiring
temperature cycling (PCR and ligase chain reaction) and (ii)
isothermal systems [transcription-based amplification sys-
tems (3SR and NASBA), strand-displacement amplification,
and QP replication systems]. Two aspects are frequent ca-
veats in these procedures: fidelity of synthesis and length of
the amplified product. As it has been recently reported, the
use of proofreading polymerases (containing 3' -- 5' exonu-
clease activity) in combination with 3' -- 5' exo-deficient
enzymes significantly increases not only fidelity but also the
size limit of the amplification reaction (32, 33).
The results presented in this paper establish basic require-
ments for the development of an amplification system relying
on the mechanism of phage 429 DNA replication. This
system would be adequate for faithful amplification of DNA
molecules longer than 70 kb (9), largely over the size limit
obtained with the amplification systems available to date.
This procedure of isothermal TP-primed amplification would
exploit the peculiar properties of 429 DNA polymerase: (i)
ability to use a protein as primer, (ii) intrinsic high proces-
sivity (>70 kb), and (iii) strand displacement coupled to DNA
synthesis. This procedure would also require the action of the
viral DBP, to efficiently recognize and activate the 429 DNA
replication origins (which should be present at the ends of the
target DNA to be amplified), and SSB, to allow maturation of
replicative intermediates and reinitiation on new DNA mol-
ecules. The sequences at 429 DNA ends that are active as
minimal replication origins (34) and the location of the protein
p6 nucleation site absolutely required for protein p6 binding
and activation of the 429 DNA replication origins (3) have
been determined. Therefore, DNA molecules suitable for
TP-primed amplification could be directly obtained by liga-
tion of double-stranded DNA fragments containing the 429
DNA replication origins to both ends of the DNA molecule
to be amplified. Alternatively, selective (targeted) amplifica-
tion would require initial stages of single-stranded DNA
priming based on the use of dual primers (specific sequence
plus 429 DNA origin sequence) to obtain specific double-
stranded DNA linear molecules flanked by 429 DNA repli-
cation origins. Once these molecules are formed and the 4)29
DNA replication proteins are provided, initiation, progres-
sion, and resolution steps would occur continuously, pro-
ducing an amplification cascade similar to that occurring
during viral infection.
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